Macrophage Dvl2 deficiency promotes NOD1-Driven pyroptosis and exacerbates inflammatory liver injury
Dishevelled 2 (Dvl2) is a key mediator of the Wingless/Wnt signaling pathway that regulates cell proliferation, migration, and immune function. However, little is known about the role of macrophage Dvl2 in modulating NOD1-mediated pyroptosis and hepatocyte death in oxidative stress-induced inflammatory liver injury. In a mouse model of oxidative stress-induced liver inflammation, mice with myeloid-specific Dvl2 knockout (Dvl2<sup>M-KO</sup>) displayed exacerbated ischemia/reperfusion (IR) stress-induced hepatocellular damage with increased serum ALT levels, oxidative stress, and proinflammatory mediators. Unlike in Dvl2<sup>FL/FL</sup> controls, Dvl2<sup>M-KO</sup> enhanced NOD1, caspase-1, GSDMD, and NF-κB activation in liver macrophages after IR. Interestingly, IR stress enhanced YAP colocalized with HSF1 in Dvl2<sup>FL/FL</sup> macrophages, while macrophage Dvl2 deficiency reduced YAP and HSF1 colocalization in the nucleus under inflammatory conditions. Importantly, Dvl2 deletion diminished nuclear YAP interacted with HSF1 and augmented NOD1/caspase-1 and GSDMD activation in response to inflammatory stimulation. However, Dvl2 activation increased YAP interaction with HSF1 and activated HSF1 target gene eEF2, inhibiting NOD1/caspase-1, GSDMD, and NF-κB activity. Moreover, macrophage eEF2 deletion increased the NOD1-caspase-1 interaction, GSDMD activation, HMGB1 release, and hepatocyte LDH release after macrophage/hepatocyte co-culture. Adoptive transfer of eEF2-expressing macrophages in Dvl2<sup>M-KO</sup> mice alleviated IR-triggered liver inflammation and hepatocellular damage. Therefore, macrophage Dvl2 deficiency promotes NOD1-mediated pyroptosis and exacerbates IR-induced hepatocellular death by disrupting the YAP-HSF1 axis. eEF2 is crucial for modulating NOD1-driven pyroptosis, inflammatory response, and hepatocyte death. Our findings underscore a novel role of macrophage Dvl2 in modulating liver inflammatory injury and imply the therapeutic potential in organ IRI and transplant recipients.
Authors
- X. B. Qu (ORCID: https://orcid.org/0000-0002-8202-0798)
- Yizhu Tian (ORCID: https://orcid.org/0000-0002-0782-1704)
- Mingwei Sheng (ORCID: https://orcid.org/0000-0001-6847-6345)
- Christopher King (ORCID: https://orcid.org/0000-0001-5892-2487)
- Bibo Ke (ORCID: https://orcid.org/0000-0002-1885-1538)
- Yuanbang Lin (ORCID: https://orcid.org/0000-0003-0123-1241)
- Douglas G. Farmer (ORCID: https://orcid.org/0000-0001-9080-0527)
- Changyong Li (ORCID: https://orcid.org/0000-0003-4001-037X)
- Dongwei Xu (ORCID: https://orcid.org/0000-0001-9802-0664)
- Qiang Xia (ORCID: https://orcid.org/0000-0001-9482-6951)
- Xiao Wang (ORCID: https://orcid.org/0000-0002-9647-8847)
- Tao Yang (ORCID: https://orcid.org/0000-0002-1127-9364)
- Xiyun Bian
- Longfeng Jiang (ORCID: https://orcid.org/0000-0001-8058-6838)
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
- Renji Hospital (CN)
- UCLA Medical Center (US)
Publication Details
- Journal
- Redox Biology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1016/j.redox.2024.103455
- Citations
- 8
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- National Institutes of Health